Connect Biopharma is trading at $2.33 (7.1% down) as investors lock in gains following a sharp multi-day rally driven by bullish analyst sentiment.
- The stock recently surged after Oppenheimer initiated coverage with an Outperform rating and an $8 price target.
- Shares are currently facing pressure amid broader biotech sector weakness and a rotation out of high-beta names.